news

DNA successfully cut and inserted using Class 1 CRISPR system

16
SHARES

A new study has shown that a Class 1 CRISPR gene editing system can achieve functional DNA repairs in human cells with no prominent off-target effects.

Japanese researchers led by Osaka University have described a new genome editing approach which they say brings medicine much closer to eliminating a host of diseases caused by faults in DNA.

…this Cas3-based method offers a superior alternative to Class 2 CRISPR gene editing systems”

Using a Cas3 protein-based Class 1 CRISPR system, the team successfully demonstrated both DNA deletions and insertions in human cells. Notably, the Cas3 protein-induced unidirectional deletions of large sections of DNA, setting it apart from Class 2 enzymes which usually need help to achieve such large genome edits. Most importantly though, Cas3 achieved more efficient genome editing than Cas9, with no prominent off-target effects.

“Class 2 CRISPR systems, particularly those using the Cas9 or Cas12a enzymes, are widely used for eukaryotic genome editing,” says lead author of the study Hiroyuki Morisaka. “However, these systems aren’t perfect: as well as introducing unintended mutations, genome editing efficiencies using these methods can be somewhat variable.”

Drug Target Review has just announced the launch of its NEW and EXCLUSIVE report examining the evolution of AI and informatics in drug discovery and development. 

In this 63 page in-depth report, experts and researchers explore the key benefits of AI and informatics processes, reveal where the challenges lie for the implementation of AI and how they see the use of these technologies streamlining workflows in the future. 

Also featured are exclusive interviews with leading scientists from AstraZeneca, Auransa, PolarisQB and Chalmers University of Technology.

FREE DOWNLOAD HERE

To confirm the therapeutic potential of the system, the researchers carried out Cas3-based repair of the DMD gene in induced pluripotent stem cells from a patient with Duchenne muscular dystrophy.

“Our results suggest that this Cas3-based method offers a superior alternative to Class 2 CRISPR gene editing systems,” said senior author Tomoji Mashimo. “As well as its obvious therapeutic uses, we envisage potential applications in drug discovery, disease prevention and crop improvement.”

The study was published in Nature Communications.